Aridis Pharmaceuticals Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb that is in Phase IIa trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 to treat infections caused by A. baumannii; AR-201, an anti- respiratory syncytial virus F-protein mAb; and AR-501, an anti-infective therapy to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. Aridis Pharmaceuticals Inc. was founded in 2003 and is headquartered in San Jose, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone408-385-1742
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/26/2019 (Estimated)
OptionableNot Optionable
Aridis Pharmaceuticals (NASDAQ:ARDS) Frequently Asked Questions
What is Aridis Pharmaceuticals' stock symbol?
Aridis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARDS."
How were Aridis Pharmaceuticals' earnings last quarter?
Aridis Pharmaceuticals Inc (NASDAQ:ARDS) released its quarterly earnings results on Tuesday, November, 13th. The company reported ($1.97) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.05) by $0.92. The company earned $1.02 million during the quarter, compared to analysts' expectations of $0.33 million. View Aridis Pharmaceuticals' Earnings History.
When is Aridis Pharmaceuticals' next earnings date?
What price target have analysts set for ARDS?
5 brokerages have issued twelve-month price objectives for Aridis Pharmaceuticals' stock. Their predictions range from $23.00 to $40.00. On average, they expect Aridis Pharmaceuticals' stock price to reach $28.25 in the next twelve months. This suggests a possible upside of 156.8% from the stock's current price. View Analyst Price Targets for Aridis Pharmaceuticals.
What is the consensus analysts' recommendation for Aridis Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aridis Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aridis Pharmaceuticals.
What are Wall Street analysts saying about Aridis Pharmaceuticals stock?
Here are some recent quotes from research analysts about Aridis Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Aridis Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the discovery and development of immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. The company's product pipeline consists of AR-301, AR-105, AR-101, AR-401, AR-201 and AR-501 which are in clinical stages. Aridis Pharmaceuticals, Inc. is based in San Jose, United States. " (1/14/2019)
- 2. Cantor Fitzgerald analysts commented, "ARDS is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. We expect upward earnings revisions and multiple expansion to move ARDS’s stock higher. That should be driven by the successful advancement of ARDS’s pipeline. Valuation Summary We used a blend of DCF and EV/EBITDA analyses to arrive at our 12-month PT of $25." (1/9/2019)
- 3. Maxim Group analysts commented, "Aridis announced that the first subject has been enrolled in its P1/2a study evaluating AR-501 for the treatment of chronic bacterial lung infections in patients with cystic fibrosis (CF)." (12/12/2018)
Has Aridis Pharmaceuticals been receiving favorable news coverage?
Headlines about ARDS stock have trended somewhat negative recently, according to InfoTrie. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Aridis Pharmaceuticals earned a news sentiment score of -1.1 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the company's share price in the near term.
Who are some of Aridis Pharmaceuticals' key competitors?
Some companies that are related to Aridis Pharmaceuticals include Osmotica Pharmaceuticals (OSMT), Karyopharm Therapeutics (KPTI), American Brivision (Holding) (ABVC), Verrica Pharmaceuticals (VRCA), Aduro BioTech (ADRO), Lannett (LCI), Geron (GERN), Protagonist Therapeutics (PTGX), AC Immune (ACIU), Strongbridge Biopharma (SBBP), Syros Pharmaceuticals (SYRS), Savara (SVRA), Merus (MRUS), Kala Pharmaceuticals (KALA) and Immune Design (IMDZ).
What other stocks do shareholders of Aridis Pharmaceuticals own?
Who are Aridis Pharmaceuticals' key executives?
Aridis Pharmaceuticals' management team includes the folowing people:
- Dr. Eric J. Patzer, Exec. Chairman of Directors (Age 70)
- Dr. Vu L. Truong, Founder, CEO, Chief Scientific Officer & Director (Age 55)
- Dr. Alan H. Cohen, Sr. VP of Clinical & Medical Affairs (Age 58)
- Mr. Fred Kurland, Chief Financial Officer (Age 68)
- Mr. Jeffrey J. Fessler J.D., Acting Gen. Counsel (Age 56)
When did Aridis Pharmaceuticals IPO?
(ARDS) raised $28 million in an initial public offering on Tuesday, August 14th 2018. The company issued 2,000,000 shares at a price of $13.00-$15.00 per share. Cantor served as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers.
When did the company's lock-up period expire?
Aridis Pharmaceuticals' lock-up period expired on Monday, February 11th. Aridis Pharmaceuticals had issued 2,000,000 shares in its public offering on August 14th. The total size of the offering was $26,000,000 based on an initial share price of $13.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the end of the lock-up period.
Who are Aridis Pharmaceuticals' major shareholders?
Aridis Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Millennium Management LLC (0.15%).
Which institutional investors are selling Aridis Pharmaceuticals stock?
ARDS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC.
How do I buy shares of Aridis Pharmaceuticals?
Shares of ARDS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aridis Pharmaceuticals' stock price today?
One share of ARDS stock can currently be purchased for approximately $11.00.
How big of a company is Aridis Pharmaceuticals?
Aridis Pharmaceuticals has a market capitalization of $89.10 million.
What is Aridis Pharmaceuticals' official website?
How can I contact Aridis Pharmaceuticals?
Aridis Pharmaceuticals' mailing address is 5941 OPTICAL COURT, SAN JOSE CA, 95138. The company can be reached via phone at 408-385-1742 or via email at [email protected]
MarketBeat Community Rating for Aridis Pharmaceuticals (NASDAQ ARDS)
MarketBeat's community ratings are surveys of what our community members think about Aridis Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARDS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARDS will underperform the S&P 500 over the long term. You may vote once every thirty days.
